3bb03dc9-6daf-42ef-95d6-cdf726f926e8
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.600
- G2M_CHECKPOINT+0.500
- PROTEIN_SECRETION+0.400
- GLYCOLYSIS+0.300
- MITOTIC_SPINDLE+0.300
- MYC_TARGETS_V1+0.300
- SPERMATOGENESIS+0.300
- CHOLESTEROL_HOMEOSTASIS+0.200
- DNA_REPAIR+0.200
- MTORC1_SIGNALING+0.200
Top 10 suppressed
- ALLOGRAFT_REJECTION-0.500
- IL6_JAK_STAT3_SIGNALING-0.500
- INFLAMMATORY_RESPONSE-0.500
- INTERFERON_GAMMA_RESPONSE-0.500
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.400
- INTERFERON_ALPHA_RESPONSE-0.400
- ANGIOGENESIS-0.300
- IL2_STAT5_SIGNALING-0.300
- KRAS_SIGNALING_UP-0.300
- MYOGENESIS-0.300
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MDT-AP-0540 | Med | Medulloblastoma | 0.867 |
| 2 | 236350e9-8964-42ae-8880-d2f2281ff993 | — | — | 0.866 |
| 3 | 13649cf2-1dc4-408f-9063-31a2b9bb7157 | — | — | 0.857 |
| 4 | SRR8518295 | — | E | 0.855 |
| 5 | TCGA-E2-A15T-01A-11R-A115-07 | — | B | 0.854 |
| 6 | TCGA-O2-A5IB-01A-11R-A27Q-07 | — | cohortMD1 | 0.854 |
| 7 | SRR5088814 | — | — | 0.853 |
| 8 | C3L-02649 | — | cohortMD1 | 0.853 |
| 9 | TCGA-22-4591-01A-01R-1201-07 | — | cohortSQ1 | 0.850 |
| 10 | SRR23303743 | — | — | 0.849 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 14 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.600 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.500 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.400 | Remibrutinib | — uncovered |
| GLYCOLYSIS | 0.300 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.300 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.300 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.300 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.200 | Remibrutinib | — uncovered |
| DNA_REPAIR | 0.200 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.200 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.200 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.100 | Idelalisib | — uncovered |
| PEROXISOME | 0.100 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.100 | Inavolisib | — uncovered |